Search
Meningococcal polysaccharide vaccine group C
go.drugbank.com/drugs/DB13890ApprovedInvestigationalIt is subcutaneously administered as an active immunization against the invasive meningococcal disease caused by the serogroup C.
Mixtures: Mencevax Ac Pws 50mcg/vial, Mencevax Ac Pws 500mcg/vialVayarin
go.drugbank.com/drugs/DB09328ApprovedThis drug has also been used for management of hypertriglyceridemia [L1503]. … A slow response time of 12 weeks is an impediment to successful management of ADHD as only 41.6% of subjects prescribed Vayarin remained compliant for the duration of the study.
Ozanimod
go.drugbank.com/drugs/DB12612ApprovedInvestigationalIt was developed by Celgene (now acquired by Bristol-Myers Squibb) [L11025] and was approved by the FDA on March 26, 2020. … [L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020.
Lumacaftor
go.drugbank.com/drugs/DB09280ApprovedInvestigational[A20301] When used in combination with [DB08820] as the fixed dose combination product Orkambi, lumacaftor is specific for the management of CF in patients with delta-F508 mutations as it acts as a protein-folding … The most common mutation, affecting approximately 70% of patients with CF worldwide, is known as F508del-CFTR, or delta-F508 (ΔF508), in which a deletion in the amino acid phenylalanine at position 508
Nonacog beta pegol
go.drugbank.com/drugs/DB13933ApprovedInvestigational[L41185] Nonacog beta pegol was approved by Health Canada on November 29, 2017.[L43682] … It is produced without animal-derived materials and with an attached 40kDa polyethylene glycol (PEG) molecule for peptide activation by a site-directed glycoPEGylation.
Phenindione
go.drugbank.com/drugs/DB00498ApprovedInvestigationalAn indandione that has been used as an anticoagulant. Phenindione has actions similar to warfarin, but it is now rarely employed because of its higher incidence of severe adverse effects. … (From Martindale, The Extra Pharmacopoeia, 30th ed, p234)
Lofexidine
go.drugbank.com/drugs/DB04948ApprovedInvestigational[A33084] It was first studied for use as an antihypertensive in 1980, but its researched was stopped as it was found less effective for the treatment of hypertension than clonidine. … [T209] Lofexidine was developed by US Woldmeds LLC and it was approved by the FDA on May 16, 2018.[L2794]
Sepiapterin
go.drugbank.com/drugs/DB16326ApprovedInvestigationalIt is a natural precursor of the enzymatic co-factor tetrahydrobiopterin (BH4), which activates PAH and helps reduce blood phenylalanine levels by enhancing the conformational stability of misfolded PAH … Sepiapterin is a small molecule activator of phenylalanine hydroxylase (PAH) used to reduce phenyalanine levels in patients with phenylketonuria.
Lecanemab
go.drugbank.com/drugs/DB14580ApprovedInvestigational[A253962,L44547] On January 6, 2023, lecanemab was granted accelerated approval by the FDA for the treatment of Alzheimer’s Disease.[L44547] It was granted full FDA approval on July 6, 2023. … [A253947,A253957] In clinical trials, it significantly reduced brain Aβ plaques compared to placebo.
Glutamic acid
go.drugbank.com/drugs/DB00142ApprovedInvestigationalNutraceuticalA peptide that is a homopolymer of glutamic acid.
Mixtures: LEVAMIN PAD, Olimel 7.6% EProducts: Glutamic Acid HCl Cap 325mg